

Raymond Y Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1274491/publications.pdf>

Version: 2024-02-01

129
papers

7,568
citations

94269

37
h-index

58464

82
g-index

132
all docs

132
docs citations

132
times ranked

10684
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	0.6	38
2	Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. <i>Neuro-Oncology</i> , 2022, 24, 289-299.	0.6	28
3	Artificial intelligence for prediction of COVID-19 progression using CT imaging and clinical data. <i>European Radiology</i> , 2022, 32, 205-212.	2.3	42
4	Standardized Classification of Lumbar Spine Degeneration on Magnetic Resonance Imaging Reduces Intra- and Inter-subspecialty Variability. <i>Current Problems in Diagnostic Radiology</i> , 2022, 51, 491-496.	0.6	4
5	Imaging Advances for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 43-61.	0.9	4
6	Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma. <i>Neuro-Oncology</i> , 2022, 24, 482-491.	0.6	3
7	Deep learning approaches to non-invasively assess molecular features of gliomas. <i>Neuro-Oncology</i> , 2022, 24, 653-654.	0.6	2
8	An automated COVID-19 triage pipeline using artificial intelligence based on chest radiographs and clinical data. <i>Npj Digital Medicine</i> , 2022, 5, 5.	5.7	22
9	Is this good enough? On expert perception of brain tumor segmentation quality. , 2022, , .		0
10	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	3.2	20
11	Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. <i>Cancer Imaging</i> , 2022, 22, 19.	1.2	9
12	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
13	Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma. <i>American Journal of Neuroradiology</i> , 2022, 43, 675-681.	1.2	12
14	Evaluation of a convolutional neural network for ovarian tumor differentiation based on magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 4960-4971.	2.3	35
15	Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. <i>European Radiology</i> , 2021, 31, 4114-4129.	2.3	22
16	Diagnostic Yield of Body CT and Whole-Body FDG PET/CT for Initial Systemic Staging in Patients With Suspected Primary CNS Lymphoma: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2021, 216, 1172-1182.	1.0	9
17	Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab088.	0.4	2
18	The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis. <i>European Radiology</i> , 2021, 31, 5289-5299.	2.3	26

#	ARTICLE	IF	CITATIONS
19	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean Journal of Radiology, 2021, 22, 584.	1.5	12
20	The Incidence of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1785.	1.7	16
21	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	0.6	45
22	Encephalopathy at admission predicts adverse outcomes in patients with SARS-CoV-2 infection. CNS Neuroscience and Therapeutics, 2021, 27, 1127-1135.	1.9	3
23	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 3369.	1.7	8
24	Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis. American Journal of Roentgenology, 2021, 217, 1184-1193.	1.0	13
25	In search of predictive and response markers in antiangiogenic therapy of glioblastoma. Neuro-Oncology, 2021, 23, 184-185.	0.6	0
26	BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas. Neuro-Oncology, 2021, , .	0.6	0
27	Identification and Characterization of Leptomeningeal Metastases Using SPINE, A Web-Based Collaborative Platform. Journal of Neuroimaging, 2021, 31, 324-333.	1.0	3
28	Biopsy Artifact in Laser Interstitial Thermal Therapy: A Technical Note. Frontiers in Oncology, 2021, 11, 746416.	1.3	3
29	NIMG-24. RANO CRITERIA DETECTS EARLY PROGRESSION SOONER THAN MODIFIED RANO CRITERIA IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi133-vi133.	0.6	0
30	Intra- and Intersubspecialty Variability in Lumbar Spine MRI Interpretation: A Multireader Study Comparing Musculoskeletal Radiologists and Neuroradiologists. Current Problems in Diagnostic Radiology, 2020, 49, 182-187.	0.6	11
31	Frequency and Evolution of New Postoperative Enhancement on 3 Tesla Intraoperative and Early Postoperative Magnetic Resonance Imaging. Neurosurgery, 2020, 87, 238-246.	0.6	5
32	Whole-Brain MR Spectroscopy Imaging of Brain Tumor Metabolites. Radiology, 2020, 294, 598-599.	3.6	5
33	Non-invasive diagnosis of H3 K27M mutant midline glioma. Neuro-Oncology, 2020, 22, 309-310.	0.6	3
34	Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. Neurologic Clinics, 2020, 38, 95-113.	0.8	21
35	Target-specific yield rate and clinical utility of percutaneous tissue sampling in spinal infection. Clinical Imaging, 2020, 68, 257-262.	0.8	4
36	Automatic Machine Learning to Differentiate Pediatric Posterior Fossa Tumors on Routine MR Imaging. American Journal of Neuroradiology, 2020, 41, 1279-1285.	1.2	37

#	ARTICLE	IF	CITATIONS
37	Differentiation of low and high grade renal cell carcinoma on routine MRI with an externally validated automatic machine learning algorithm. <i>Scientific Reports</i> , 2020, 10, 19503.	1.6	12
38	Response to Letter to Editor. <i>Neuro-Oncology</i> , 2020, 22, 1706-1707.	0.6	1
39	Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Nonâ€“Small Cell Lung Cancer. <i>Radiology</i> , 2020, 297, 419-427.	3.6	21
40	Ivosidenib in Isocitrate Dehydrogenase 1<i>â€“</i>Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	0.8	167
41	Deep Learning Based on <sc>MRI</sc> for Differentiation of Lowâ€“and Highâ€“Grade in Lowâ€“Stage Renal Cell Carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1542-1549.	1.9	31
42	Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data. <i>Neuro-Oncology</i> , 2020, 22, 1536-1544.	0.6	10
43	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	0.6	131
44	Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging. <i>Clinical Cancer Research</i> , 2020, 26, 1944-1952.	3.2	86
45	CerebroVis: Designing an Abstract yet Spatially Contextualized Cerebral Artery Network Visualization. <i>IEEE Transactions on Visualization and Computer Graphics</i> , 2020, 26, 938-948.	2.9	8
46	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
47	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. <i>Neuro-Oncology</i> , 2020, 22, 1822-1830.	0.6	23
48	Artificial Intelligence Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT. <i>Radiology</i> , 2020, 296, E156-E165.	3.6	315
49	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
50	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii11-ii11.	0.6	1
51	Standardization of imaging methods for machine learning in neuro-oncology. <i>Neuro-Oncology Advances</i> , 2020, 2, iv49-iv55.	0.4	8
52	Indications and Limitations of Conventional ImagingÂ€“ Current Clinical Practice in theÂ€“Context of Standard Therapy. , 2020, , 1-15.		1
53	BIOM-34. CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii8-ii9.	0.6	0
54	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. <i>Neuro-Oncology</i> , 2019, 21, 234-241.	0.6	16

#	ARTICLE	IF	CITATIONS
55	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	0.6	114
56	Using 3D MRI Anatomic Maps to Determine Prognosis for Glioblastomas. <i>Radiology</i> , 2019, 293, 644-645.	3.6	0
57	Survival Benefit of Adjuvant Radiotherapy in Elderly Patients with WHO Grade III Meningioma. <i>World Neurosurgery</i> , 2019, 131, e303-e311.	0.7	10
58	The effect of brain metastasis location on clinical outcomes: A review of the literature. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz017.	0.4	11
59	Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 142, 299-307.	1.4	98
60	Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell lymphoma of head and neck with extranodal involvement. <i>Hematology</i> , 2019, 24, 268-275.	0.7	4
61	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	0.6	102
62	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	0.6	184
63	Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. <i>Neuro-Oncology</i> , 2019, 21, 1412-1422.	0.6	128
64	A low percentage of metastases in deep brain and temporal lobe structures. <i>Neuro-Oncology</i> , 2019, 21, 640-647.	0.6	8
65	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	157.7	965
66	DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi73-vi73.	0.6	0
67	NIMG-43. LONGITUDINAL TRACKING AND GROWTH RATE CHARACTERIZATION OF BRAIN METASTASES ON MAGNETIC RESONANCE IMAGING. <i>Neuro-Oncology</i> , 2019, 21, vi170-vi171.	0.6	0
68	Teaching NeuroImages: Corkscrew medullary veins in active neurosarcoidosis. <i>Neurology</i> , 2019, 93, e1832-e1833.	1.5	0
69	MR Imaging of the Extracranial Facial Nerve with the CISS Sequence. <i>American Journal of Neuroradiology</i> , 2019, 40, 1954-1959.	1.2	12
70	CT-Guided Percutaneous Spine Biopsy Specimen Adequacy, Pathology Concordance, and Negative Predictive Value with Battery-Powered Drill and Manual Approaches. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 558-562.	0.6	3
71	Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. <i>World Neurosurgery</i> , 2019, 122, e108-e120.	0.7	5
72	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. <i>Neuro-Oncology</i> , 2019, 21, i32-i43.	0.6	56

#	ARTICLE	IF	CITATIONS
73	Functional MRI Task Comparison for Language Mapping in Neurosurgical Patients. Journal of Neuroimaging, 2019, 29, 348-356.	1.0	28
74	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	0.6	100
75	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	0.6	92
76	Improved Optic Nerve Visualization and Surgical Planning through a Novel MRI Protocol. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, .	0.4	0
77	Imaging in neuro-oncology. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875986.	1.5	41
78	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	0.6	64
79	Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base. World Neurosurgery, 2018, 112, e812-e822.	0.7	21
80	Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro-Oncology, 2018, 20, 1262-1271.	0.6	31
81	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology, 2018, 20, 1162-1172.	0.6	92
82	Imaging Neurologic Manifestations of Oncologic Disease. , 2018, , 13-31.		0
83	Residual Convolutional Neural Network for the Determination of <i>IDH</i> Status in Low- and High-Grade Gliomas from MR Imaging. Clinical Cancer Research, 2018, 24, 1073-1081.	3.2	297
84	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. Neuro-Oncology, 2018, 20, vi159-vi159.	0.6	0
85	Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study. American Journal of Neuroradiology, 2018, 39, 2187-2193.	1.2	61
86	NIMG-54. SPATIAL DISTRIBUTION ATLASES OF POST-TREATMENT MRI SCANS REVEAL DISTINCT HEMISPHERIC DISTRIBUTION OF GLIOBLASTOMA RECURRENCE FROM PSEUDO-PROGRESSION. Neuro-Oncology, 2018, 20, vi188-vi188.	0.6	0
87	Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. American Journal of Roentgenology, 2018, 211, 1342-1347.	1.0	10
88	PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology, 2018, 91, e1355-e1359.	1.5	64
89	CT and MRI Protocol Variation and Optimization at an Academic Medical Center. Journal of the American College of Radiology, 2018, 15, 1254-1258.	0.9	12
90	Assessment of care pattern and outcome in hemangioblastoma. Scientific Reports, 2018, 8, 11144.	1.6	13

#	ARTICLE	IF	CITATIONS
91	Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients. <i>World Neurosurgery</i> , 2018, 118, e375-e387.	0.7	18
92	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	0.8	15
93	Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 139, 563-571.	1.4	17
94	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 109-117.	0.6	211
95	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	0.6	84
96	An Update on the Approach to the Imaging of Brain Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 53.	2.0	11
97	Response assessment in high-grade glioma: tumor volume as endpoint. <i>Neuro-Oncology</i> , 2017, 19, 744-745.	0.6	6
98	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	3.2	53
99	MNGI-10. SURVIVAL BENEFIT ASSOCIATED WITH ADJUVANT RADIOTHERAPY IN ELDERLY PATIENTS WITH WHO GRADE III MENINGIOMA. <i>Neuro-Oncology</i> , 2017, 19, vi134-vi134.	0.6	0
100	Radiographic Prediction of Meningioma Grade and Genomic Profile. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.4	1
101	Radiographic prediction of meningioma grade by semantic and radiomic features. <i>PLoS ONE</i> , 2017, 12, e0187908.	1.1	109
102	Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. <i>Neuro-Oncology</i> , 2016, 18, 1680-1687.	0.6	94
103	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. <i>Diagnostic Pathology</i> , 2016, 11, 13.	0.9	10
104	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 705-718.	0.6	25
105	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62
106	Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response. <i>Frontiers in Neurology</i> , 2015, 6, 33.	1.1	139
107	How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 343.	0.7	13
108	The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study). <i>American Journal of Neuroradiology</i> , 2015, 36, 1589-1598.	1.2	21

#	ARTICLE	IF	CITATIONS
109	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , 2015, 16, e534-e542.	5.1	582
110	Early Postoperative Imaging and Image-Guided Procedures on Patients with Face Transplants. <i>American Journal of Neuroradiology</i> , 2015, 36, 568-574.	1.2	6
111	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. <i>Neuro-Oncology</i> , 2014, 16, 1523-1529.	0.6	22
112	Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2014, 119, 149-158.	1.4	41
113	Defining language networks from resting-state fMRI for surgical planning—a feasibility study. <i>Human Brain Mapping</i> , 2014, 35, 1018-1030.	1.9	176
114	Effect of region-of-interest placement in bolus tracking cerebral computed tomography angiography. <i>Neuroradiology</i> , 2013, 55, 1183-1188.	1.1	3
115	Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. <i>Journal of Neuro-Oncology</i> , 2013, 115, 267-276.	1.4	30
116	Effect of disease and recovery on functional anatomy in brain tumor patients: insights from functional MRI and diffusion tensor imaging. <i>Imaging in Medicine</i> , 2013, 5, 333-346.	0.0	14
117	Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. <i>Cancer</i> , 2013, 119, 3479-3488.	2.0	26
118	Recurrent glioblastoma: Stratification of patient survival using tumor volume before and after antiangiogenic treatment. <i>Journal of Clinical Oncology</i> , 2013, 31, 2075-2075.	0.8	2
119	Semi-Automatic Segmentation Software for Quantitative Clinical Brain Glioblastoma Evaluation. <i>Academic Radiology</i> , 2012, 19, 977-985.	1.3	33
120	Diagnosis and treatment of a perforated duodenal diverticulum. <i>Emergency Radiology</i> , 2007, 13, 285-287.	1.0	13
121	Metalloproteomics: High-Throughput Structural and Functional Annotation of Proteins in Structural Genomics. <i>Structure</i> , 2005, 13, 1473-1486.	1.6	76
122	<i>C. elegans</i> ORFeome version 1.1: experimental verification of the genome annotation and resource for proteome-scale protein expression. <i>Nature Genetics</i> , 2003, 34, 35-41.	9.4	347
123	High-throughput expression, purification, and characterization of recombinant <i>Caenorhabditis elegans</i> proteins. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 928-934.	1.0	23
124	In situ chemistry of osteoporosis revealed by synchrotron infrared microspectroscopy. <i>Bone</i> , 2003, 33, 514-521.	1.4	72
125	Characterization of bone mineral composition in the proximal tibia of <i>Cynomolgus</i> monkeys: effect of ovariectomy and nandrolone decanoate treatment. <i>Bone</i> , 2002, 30, 492-497.	1.4	66
126	Center for Synchrotron Biosciences' U2B beamline: an international resource for biological infrared spectroscopy. <i>Journal of Synchrotron Radiation</i> , 2002, 9, 189-197.	1.0	86

#	ARTICLE	IF	CITATIONS
127	Structural genomics: A pipeline for providing structures for the biologist. Protein Science, 2002, 11, 723-738.	3.1	168
128	Performance of Automatic Machine Learning versus Radiologists in the Evaluation of Endometrium on Computed Tomography. SSRN Electronic Journal, 0, , .	0.4	0
129	Differentiation of Low and High Grade Renal Cell Carcinoma on Routine MR with an Externally Validated Automatic Machine Learning Algorithm. SSRN Electronic Journal, 0, , .	0.4	0